Invivyd stock maintains Buy rating at BTIG, $10 target
BTIG maintained a Buy rating and $10.00 price target on Invivyd Inc. (NASDAQ:IVVD), citing upcoming immunogenicity data from the DECLARATION trial. The stock is trading at $0.56, down 76% year-to-date. The company reported positive results from the LIBERTY trial for VYD2311, with strong safety and tolerability compared to an mRNA vaccine. Invivyd has a 92% gross profit margin but is burning through cash quickly.
